Glucose metabolism abnormalities after acute myocardial infarction in patients with one-vessel coronary artery disease, treated with primary percutaneous coronary intervention - 1-year follow-up;Roczna obserwacja zaburzeń gospodarki weglowodanowej u osób po zawale serca z choroba jednonaczyniowa leczonych pierwotna angioplastyka

Przeglad Kardiodiabetologinczny

Volumn 4, Issue 1, 2009, Pages 3-10

  Lewczuk, Anna ^a   Hirnle, Tomasz ^a   Sobkowicz, Bozena ^a   Sawicki, Robert ^a   Tomaszuk Kazberuk, Anna ^a   Knapp, Malgorzata ^a   Musial, Włodzimierz ^a   Juszczyk, Grzegorz ^a   Jakubów, Piotr ^a   Cydzik, Mariusz ^a  

^a Samodzielny Publiczny Dzieci cy Szpital Kliniczny   (Poland)

Author keywords

Diabetes mellitus; Disturbances of glucose metabolism; Myocardial infarction; Primary percutaneous coronary intervention

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PROGNOSIS; TREATMENT RESPONSE;

EID: 77953458884     PISSN: 18969666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360: 825-9.
2. Timmer JR, Ottervanger JP, Thomas K, et al. On behalf of the Zwolle myocardial infarction study group. Long-term, causespecific mortality after myocardial infarction in diabetes. Eur Heart J 2004; 25: 926-31.
3. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998; 82: 515-8.
4. Gustafsson I, Hildebrandt P. Blood glucose in the CCU: time to measure. Eur Heart J 2001; 22: 1061-2.
5. Marfella R, Siniscalchi M, Esposito K, et al. Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Diabetes Care 2003; 26: 3129-35.
6. Kashiwagi A, Asahina T, Nishio Y, et al. Glycation, oxidative stress, and scavenger activity: glucose metabolism and radical scavenger dysfunction in endothelial cells. Diabetes 1996; 45 Suppl 3: S84-6.
7. Stranders I, Diamant M, van Gelder RE, et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med 2004; 164: 982-8.
8. Aguilar D, Solomon SD, Køber L, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004; 110: 1572-8.
9. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-7.
10. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41: 202-8.
11. Park S, Barrett-Connor E, Wingard DL, et al. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care 1996; 19: 450-6.